SNWV SANUWAVE Health, Inc. Insider Trading

10% owner Opaleye Management sells ~71K shares across two days as SNWV stock slides from recent highs

Opaleye Management, a substantial institutional holder owning more than 10% of SANUWAVE, executed a multi-day sale totaling approximately $1.3 million in shares on April 28-29. The timing is notable: the stock has fallen significantly from its recent highs and is now trading well below where it was trading even thirty and ninety days ago, suggesting this liquidation came during a period of downward momentum. However, this transaction reflects routine portfolio rebalancing by an investment fund, not insider knowledge—Opaleye holds no operational role at the company. The company itself remains profitable with strong revenue growth and a reasonable valuation, so the fund's sale appears driven by portfolio management considerations rather than a loss of confidence in the business fundamentals. For investors, this filing is mostly administrative in nature and should not be interpreted as an executive abandoning ship.

10% owner Manchester Management sells 144,810 shares (-98.6%) for $4.5M at $30.73 avg; retains 2,000 shares

Manchester Management CO LLC, a 10% shareholder, executed 4 separate sales totaling 144,810 shares for $4,450,061.36 across three trading days (Dec 8–10, 2025), reducing holdings from 146,810 shares to 2,000 shares. This represents a near-complete exit of the position, with the insider retaining minimal exposure after the blended average sale price of $30.73. The magnitude of the reduction (-98.6% of pre-transaction holdings) and the retention of only 2,000 shares signals a material shift in the 10% owner's capital allocation or strategic posture toward SNWV, warranting investor scrutiny into what drove such a substantial liquidation.

10% Owner Opaleye Management buys 1,267 shares of SNWV at $30.28; prior two purchases at this ticker both returned +40.2% over 90 days.

Opaleye Management, a 10% shareholder, purchased 1,267 shares at $30.28, adding to a position now totaling 966.3K shares. The stock currently trades at $32.21, and while it has declined 28.4% from its 52-week high and fallen 10.8% over the past 30 days, Opaleye's prior purchase history at this ticker is noteworthy: two earlier buys (both on 2025-04-29) each delivered +40.2% returns over 90 days, indicating well-timed entry points. The insider's cross-ticker track record shows 20 prior buys averaging +8.9% 30-day returns and +20.2% 90-day returns with a 100% win rate. Against this backdrop, the current purchase arrives as the stock faces near-term pressure, despite SNWV's strong fundamentals including +60% annual revenue growth and recent profitability ($1.1M net income in the latest quarter). The pattern of prior success on the same ticker, combined with entry during a pullback, warrants monitoring for whether this trade aligns with the insider's historical timing acumen.

10% Owner Opaleye Management bought 7,998 shares at $25.49, raising stake 114.2% to 15,000 shares in unprofitable SNWV

Opaleye Management, a 10% owner, executed two separate purchases totaling 7,998 shares for $203,875.42 at $25.49 per share on 2025-04-29, increasing its stake by 114.2% from 7,002 to 15,000 shares. The company remains unprofitable with a net income of $-20,657,000.00 in its most recent full fiscal year, though revenue grew 60.0% year-over-year to $9,360,000.00 in the latest quarter. The stock has declined 23.5% over the past 30 days and trades 30.1% below its 52-week high of $38.71, though the insider's cross-ticker trading history shows an average 30-day return of -19.5% on prior open-market purchases. The transaction represents a material increase in the insider's exposure to a high-growth but currently unprofitable biomedical company during a period of significant stock price weakness.

10% Owner Opaleye Management buys 27,868 shares for $438,902.36 across 5 trades (Oct 30–Nov 1, 2024)

Opaleye Management, a 10% holder of SANUWAVE Health, executed five separate purchases totaling 27,868 shares for $438,902.36 with a blended average price of $15.75, occurring immediately after the stock's 11-day public listing on November 1, 2024. The holder's position moved from -15,866 shares (short) to +12,002 shares (long), a net acquisition of the full 27,868 shares purchased. The timing coincides with the company's recent IPO window—a period when existing investors typically convert short positions or establish long positions—and the purchase prices ($17.50 down to $15.20) track the early price action in a freshly listed security. With Q1 revenue of $7.2M and quarterly net income of $6.6M offset by full-year negative profitability, the company's near-term fundamentals remain mixed, warranting close attention to whether this 10% holder's accumulation reflects confidence in post-listing trajectory or standard portfolio positioning following listing stabilization.